외용약 수탁 제조 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 사업 규모별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Topical Drugs Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type, By Scale Of Operation, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

외용약 수탁 제조시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 외용약 수탁 제조 시장은 2030년까지 545억 5,000만 달러에 달할 것으로 예측됩니다.

이 시장은 2025-2030년에 걸쳐 CAGR 11.05%로 성장할 것으로 예측되고 있습니다. 현재, 외용약의 수탁제조 세계 시장은 진화하는 치료요구, 아웃소싱 동향, 기술의 진보에 견인되어 큰 성장을 이루고 있습니다. 더욱이, 피부과 질환의 유병률 증가와 고령 인구의 증가, 그리고 크림, 젤, 연고, 스프레이, 경피 패치와 같은 비침습적 약물 전달 방식에 대한 선호가 맞물려, 비용 최적화, 규제 준수 확보, 생산 능력 향상을 위해 위탁 생산 전문 기업(CMO)과 같은 아웃소싱 서비스가 필수가 되었습니다. 또한 CMO는 업무 합리화, 사내 제조 경비 절감, 제품화 속도 향상을 지원하는 수많은 이점을 제공하여 시장 확대에 더욱 기여하고 있습니다. 용약에 대한 소비자 수요가 높아지는 가운데 아웃소싱은 전략적 우선사항이 되고 있으며, 특히 반고형제제나 경피흡수제제 등 전문적인 지식과 적응성이 높은 인프라를 필요로 하는 제품라인에서는 그 경향이 현저합니다.

게다가 시장의 성장에는 비용역학이 중요한 역할을 하고 있습니다. 인건비 하락, 정부 지원 정책, 우수 제조업 관행(GMP)에 대한 인프라 불만 제기 등의 요인이 아시아 태평양 시장을 부추기고 있습니다. 또한, 연속 제조, 나노캡슐화, 선진적 균질화, 3D 프린팅등의 기술 혁신이, 제제 정밀도, 바이오아베이라빌리티, 배치 일관성을 향상시키고 있습니다.

게다가 가격모델은 성과와 재무결과를 일치시켜 진화하고 있습니다. 그러나 수입 활성 의약품 성분(API) 및 부형제에 대한 미국의 관세와 같은 외부 요인으로 인해 공급망에 비용 압박이 발생했으며, 특히 수출업체에 영향을 미쳤습니다. 이러한 과제에도 불구하고, 시장은 예측 기간 동안 성장할 것으로 예측됩니다. Arcutis BIoTherapeutics, Inc.는 성인과 6세 이하의 소아에 있어서의 경도에서 중등도의 아토피 피부염의 치료를 적응으로 하는 ZORYVE 크림 0.15%를 미국에서 발매한다고 발표했습니다. 이를 적용하면 스테로이드를 포함하지 않고 증상을 신속하게 완화하고 가려움증을 줄이기 때문에 장기간의 관리가 가능합니다.

외용약 수탁 제조 시장 보고서 하이라이트

• 반고형제제부문이 시장을 독점하고 2024년의 점유율은 65.54%였습니다.
• 사업 규모별로는 2024년에는 상업부문이 최대 시장 점유율을 차지했습니다.
• 2024년의 최종 용도별 시장 점유율은 제약 기업이 가장 높았습니다. 이러한 기업은 비침습적 치료, 만성 피부 질환의 치료, 환자의 컴플라이언스 향상, 미용 피부과나 선진적 경피 약물전달 시스템에 있어서의 기회 증가 등 수요 증가에 의해 CMO 서비스를 활용하고 있습니다.
• 북미는 미국이나 캐나다 등에서 제조 수탁기관(CMO)의 수가 증가하고 있기 때문에 예측 기간 동안 CAGR 10.37%로 성장할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 외용약 수탁 제조 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 가격 모델 분석
• 기술
• 시장 분석 도구
  • Porter's Five Forces 분석
  • SWOT 분석에 의한 PESTEL
  • COVID-19의 영향 분석

제4장 외용약 수탁 제조 시장 : 제품 유형별, 추정·동향 분석

• 외용약 수탁 제조 시장(제품 유형별) : 부문 대시보드
• 외용약 수탁 제조 시장(제품 유형별) : 변동 분석
• 제품 유형별, 2018-2030년
• 반고형 제제
  • 크림
  • 연고
  • 겔
  • 기타
• 액체 제형
• 고형 제제
• 경피 흡수형 제품

제5장 외용약 수탁 제조 시장 : 사업 규모별, 추정·동향 분석

• 외용약 수탁 제조 시장(사업 규모별) : 부문 대시보드
• 외용약 수탁 제조 시장(사업 규모별) : 변동 분석
• 사업 규모별, 2018-2030년
• 임상
• 상용

제6장 외용약 수탁 제조 시장 : 최종 용도별, 추정·동향 분석

• 외용약 수탁 제조 시장(최종 용도별) : 부문 대시보드
• 외용약 수탁 제조 시장(최종 용도별) : 변동 분석
• 최종 용도별, 2018-2030년
• 제약회사
• 바이오의약품기업
• 기타

제7장 외용약 수탁 제조 시장 :지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 덴마크
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 태국
  • 한국
  • 호주
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 시장 진출기업의 분류
• 기업의 시장 점유율/평가 분석, 2024년
• 기업 프로파일
  • MedPharm
  • DPT Laboratories Ltd
  • Cambrex Corporation
  • Kindeva Drug Delivery
  • AbbVie Contract Manufacturing
  • NextPharma
  • Catalent Pharma Solutions
  • Thermo Fisher Scientific
  • Lonza Group
  • The Lubrizol Corporation
  • SGS SA
  • Bora Pharmaceutical CDMO

SHW

영문 목차

영문목차

Topical Drugs Contract Manufacturing Market Growth & Trends:

The global topical drugs contract manufacturing market is expected to reach USD 54.55 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 11.05% from 2025 to 2030. Currently, the global market for contract manufacturing of topical drugs is currently experiencing significant growth, driven by evolving therapeutic needs, outsourcing trends, and advancements in technology. Moreover, with the increasing prevalence of dermatological conditions, coupled with a rising geriatric population and a preference for non-invasive drug delivery methods such as creams, gels, ointments, sprays, and transdermal patches has made outsourcing services like Contract Manufacturing Organizations (CMOs) essential for optimizing costs, ensuring regulatory compliance, and enhancing production capabilities. In addition, CMOs offer numerous advantages that support streamline operations, lower in-house manufacturing expenses, and speed up product commercialization, further contributing to market expansion. In addition, with the rising consumer demand for topical drugs, outsourcing has become a strategic priority, particularly for semi-solid and transdermal product lines that require specialized expertise and adaptable infrastructure.

Furthermore, cost dynamics play a crucial role in the growth of the market. Based on the pricing analysis, the North America provides high-quality manufacturing that complies with regulatory standards, while the Asia Pacific's countries like India, China, and South Korea offers more cost-effective production options with growing capabilities. Factors such as lower labor costs, supportive government policies, and a developing infrastructure complaint with Good Manufacturing Practices (GMP) are fueling the market in Asia Pacific. Furthermore, technological innovations such as continuous manufacturing, nanoencapsulation, advanced homogenization, and 3D printing are improving formulation accuracy, bioavailability, and batch consistency. These advancements support the CMOs to meet complex product demands and meet rising consumer expectations for efficacy and customization.

Furthermore, pricing models are evolving with aligning financial results with performance. However, external factors like U.S. tariffs on imported active pharmaceutical ingredients (APIs) and excipients have created cost pressures in the supply chain, particularly impacting exporters. Despite these challenges, the market is expected to witness growth during the forecast period. Likewise, strategic initiatives and accelerating product launches drive the market. For instance, in July 2024, Arcutis Biotherapeutics, Inc. announced the release of ZORYVE cream 0.15% for the treatment of mild to moderate atopic dermatitis in both adults and children under 6 in the U.S. This new cream, which is applied once daily and contains no steroids, provides quick relief from symptoms and reduces itching, allowing for better long-term management of the condition. Such innovations are expected to further propel the market during the forecast period.

Topical Drugs Contract Manufacturing Market Report Highlights:

• The semi-solid formulations segment dominated the market, with a share of 65.54% in 2024. This growth is driven by the increasing prevalence of skin diseases, patient preferences for targeted therapies, the convenience of semi-solid formulations, and the demand for improved drug absorption, stability, and aesthetic appeal within both therapeutic and cosmetic sectors.
• Based on the scale of operation, the commercial segment held the largest market share in 2024, attributed to the growing trend toward outsourcing, increased demand for dermatological and transdermal therapies, regulatory compliance, increased cost efficiency, and the rising complexity of formulations that require specialized manufacturing expertise.
• The pharmaceutical companies segment held the largest market share in 2024 based on end-use. These companies leverage CMO services due to increasing demand for non-invasive therapies, treatments for chronic skin conditions, improved patient compliance, and opportunities within cosmetic dermatology and advanced transdermal drug delivery systems.
• North America is expected to register a growth rate of 10.37% CAGR over the forecast period due to the rising number of contract manufacturing organizations(CMOs) in countries such as the U.S. and Canada. In addition, the availability of a skilled workforce and regulatory scenarios are expected to significantly contribute to the market's expansion in this region.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Scale of Operation
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Topical Drugs Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Pricing Model Analysis
• 3.4. Technology Landscape
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Force Analysis
  • 3.5.2. PESTEL by SWOT Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Topical Drugs Contract Manufacturing Market: Product Type Estimates & Trend Analysis

• 4.1. Topical Drugs Contract Manufacturing Market, By Product Type: Segment Dashboard
• 4.2. Topical Drugs Contract Manufacturing Market, By Product Type: Movement Analysis
• 4.3. Topical Drugs Contract Manufacturing Market Estimates & Forecasts, By Product Type, 2018 - 2030
• 4.4. Semi-Solid Formulations
  • 4.4.1. Semi-Solid Formulations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Creams
    • 4.4.2.1. Creams Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Ointments
    • 4.4.3.1. Ointments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Gel
    • 4.4.4.1. Gel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Liquid Formulations
  • 4.5.1. Liquid Formulations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Solid Formulations
  • 4.6.1. Solid Formulations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Transdermal Products
  • 4.7.1. Transdermal Products Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Topical Drugs Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis

• 5.1. Topical Drugs Contract Manufacturing Market, By Scale of Operation: Segment Dashboard
• 5.2. Topical Drugs Contract Manufacturing Market, By Scale of Operation: Movement Analysis
• 5.3. Topical Drugs Contract Manufacturing Market Estimates & Forecasts, By Scale of Operation, 2018 - 2030
• 5.4. Clinical
  • 5.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Commercial
  • 5.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Topical Drugs Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Topical Drugs Contract Manufacturing Market, By End Use: Segment Dashboard
• 6.2. Topical Drugs Contract Manufacturing Market, By End Use: Movement Analysis
• 6.3. Topical Drugs Contract Manufacturing Market Estimates & Forecasts, By End Use, 2018 - 2030
• 6.4. Pharmaceutical Companies
  • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Biopharmaceutical Companies
  • 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Topical Drugs Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Thailand
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Australia
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Share/Assessment Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. MedPharm
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. DPT Laboratories Ltd
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Cambrex Corporation
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Kindeva Drug Delivery
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. AbbVie Contract Manufacturing
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. NextPharma
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Catalent Pharma Solutions
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Thermo Fisher Scientific
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Lonza Group
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. The Lubrizol Corporation
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. SGS S.A.
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Bora Pharmaceutical CDMO
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives

관련자료